New Guidelines on Elevated Lp(a): What Clinicians Need to Know Now

Lipoprotein(a) [Lp(a)] is a largely overlooked but clinically critical cardiovascular risk factor affecting a substantial portion of the population. Unlike LDL cholesterol, which responds meaningfully to diet and lifestyle, Lp(a) is almost entirely determined by genetics and remains remarkably stable across a person's lifetime. This stability makes it an ideal candidate for one-time screening — a fact now formalized in the 2026 ACC/AHA/Multisociety Dyslipidemia Guidelines, which recommend universal Lp(a) measurement in all adults and cascade family screening when levels are elevated.

This review article from the Journal of Clinical Endocrinology & Metabolism synthesizes current evidence on Lp(a)'s role in cardiovascular disease and provides clinicians with a practical, case-based management framework. Elevated Lp(a) is independently associated with myocardial infarction, stroke, peripheral artery disease, and calcific aortic stenosis — a constellation of age-related conditions central to longevity medicine.

Because no approved Lp(a)-specific therapy yet exists, the authors emphasize optimizing modifiable risk factors as the primary strategy. Aggressive LDL-C reduction through statins remains the cornerstone, with PCSK9 inhibitors as adjuncts for high-risk patients. Lipid apheresis — a procedure that physically removes Lp(a) from the blood — is available for extreme cases. Selective aspirin use is flagged as potentially beneficial, though guidance remains nuanced.

The most exciting horizon is pharmacologic: antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) can reduce Lp(a) levels by 80–90% and are now in Phase 3 trials. If approved, these agents would represent a paradigm shift in managing this genetically stubborn risk factor.

From a longevity standpoint, Lp(a) represents a high-impact, underdiagnosed cardiovascular biomarker. Universal screening could identify millions of adults at elevated risk who appear normal on standard lipid panels, enabling earlier, more targeted intervention to extend healthspan.